Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
05 oct. 2021 08h00 HE
|
Adaptimmune Therapeutics plc
- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS - - The Company will host its first virtual medical symposium at CTOS - ...
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
13 sept. 2021 07h00 HE
|
Adaptimmune Therapeutics plc
- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - - Majority of patients...
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
07 sept. 2021 07h00 HE
|
Adaptimmune Therapeutics plc
- Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the...
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
05 sept. 2021 06h15 HE
|
Adaptimmune Therapeutics plc
- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff - - Data presented today at the International Liver Cancer...
Adaptimmune Reports Second Quarter Financial Results and Business Update
09 août 2021 16h00 HE
|
Adaptimmune Therapeutics plc
- SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year - - SURPASS trial data from 23 evaluable patients...
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
19 mai 2021 17h00 HE
|
Adaptimmune Therapeutics plc
- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - ...
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
11 mai 2021 08h00 HE
|
Adaptimmune Therapeutics plc
- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - - HiT works as well, or better than, a TRuC...
Adaptimmune Reports First Quarter Financial Results and Business Update
06 mai 2021 07h30 HE
|
Adaptimmune Therapeutics plc
- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - - First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT - - Enrollment momentum in...
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT
27 avr. 2021 16h30 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical...
Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021
22 avr. 2021 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 22, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results...